

Performance in Delivery Benchmark

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial
12/LO/0081	92095	OCTAVE A3921096: 008: Oral CP-690, 550 as Maintenance Therapy for Ulcerative Colitis	Number Agreed	3	3	Date Agreed	30/04/2015	1	01/05/2015	Recruitment Finished
10/H1308/84	63982	NCRN252 - Nilotinib in paediatric Ph+ CML/ALL	Number Agreed	1	1	Date Agreed	31/05/2015	1	10/06/2015	Recruitment Finished
10/H0406/47	53684	ABBOTT 327 CCRN 283 (LT uveitis)	Number Agreed	8	8	Date Agreed	31/03/2018	14	03/04/2015	Recruitment Finished
12/SC/0434	109521	(MCRN194) DPM-CF-204 mannitol in CF aged 6-17	Number Agreed	4	4	Date Agreed	31/05/2015	4	27/04/2015	Recruitment Finished
13/LO/0150	119662	NCRN561 : The regorafenib in patients with hepatocellular carcinoma (RESORCE)	Number Agreed	2	2	Date Agreed	01/08/2015	1	07/10/2015	Recruitment Finished
12/NW/0641	108307	NCRN442 BRIM 8: Vemurafenib in adjuvant melanoma	Number Agreed	9	9	Date Agreed	01/12/2015	16	27/08/2015	Recruitment Finished
13/WA/0101	123496	CCRN 2088 (Pneumonia)	Number Agreed	6	6	Date Agreed	30/04/2016	0	24/09/2015	Withdrawn By Sponsor
13/LO/0418	112763	SD560 Pfizer PPHN Sildenafil A1481316 (MCRN228)	Number Agreed	2	2	Date Agreed	31/10/2017	1	18/02/2016	Withdrawn By Host
13/LO/0945	130164	MCRN 2419: KOGNITO (Kuvan??s effect on the cOGNITion of children with phenylketOnuria)	Number Agreed	2	2	Date Agreed	30/09/2015	2	30/09/2015	Recruitment Finished
12/EE/0071	92472	CCRN 923 (Ascites)	Number Agreed	6	6	Date Agreed	31/12/2014	5	02/04/2015	Recruitment Finished
13/WA/0269	136856	CCRN 771 (Endometriosis-related pain)	Number Agreed	6	6	Date Agreed	08/05/2015	3	15/05/2015	Recruitment Finished
13/WS/0304	141071	EVARREST (The Fibrin Pad CV Phase III Study)	Number Agreed	10	10	Date Agreed	31/12/2015	8	30/07/2015	Withdrawn By Sponsor
14/LO/0036	134228	NCRN2555 - TOWER Study (00103311)	Number Agreed	5	5	Date Agreed	31/01/2016	3	04/09/2015	Withdrawn By Sponsor
14/SW/0079	148012	3308 CARD DEFLECT-III	Number Agreed	6	6	Date Agreed	30/04/2015	8	30/04/2015	Recruitment Finished
13/YH/0126	126242	GWCA1208 - Study of Sativex in Patients with Recurrent Glioblastoma	Number Agreed	4	4	Date Agreed	31/08/2015	3	04/08/2015	Recruitment Finished
13/EE/0367	138166	CCRN 2215 (Crohn's)	Number Agreed	3	3	Date Agreed	30/09/2015	0	30/09/2015	Recruitment Finished
13/LO/0716	112718	CCRN 2159 (Uveitis)	Number Agreed	4	4	Date Agreed	30/06/2016	0	21/09/2015	Withdrawn By Sponsor
13/LO/0717	124878	CL3-78989-006. EYEGUARD-C study	Number Agreed	4	4	Date Agreed	30/11/2015	6	21/09/2015	Recruitment Finished
14/EM/0034	141471	NCRN3025 - GDC-0199 in CLL (GO28667) - MURANO	Number Agreed	2	2	Date Agreed	30/11/2015	1	04/09/2015	Withdrawn By Sponsor
13/LO/1608	135821	Study of efficacy and safety of nilotinib in paediatric CML patients	Number Agreed	1	1	Date Agreed	31/12/2015	1	06/07/2015	Recruitment Finished
14/EE/1001	156001	OTO-104 in Meniere's Disease	Number Agreed	5	5	Date Agreed	17/04/2015	7	17/04/2015	Recruitment Finished
14/SC/1014	156913	CANC - 3482 JANUS 1: Ruxolitinib or placebo + Capecitabine in pancreatic adenocarcinoma	Number Agreed	2	2	Date Agreed	30/09/2015	4	08/01/2016	Recruitment Finished
14/EE/1063	156834	AZD9291 v chemotherapy in NSCLC, following EGFR TKI therapy (AURA3)	Number Agreed	3	3	Date Agreed	02/09/2015	0	27/08/2015	Recruitment Finished

Performance in Delivery Benchmark

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial
14/WM/1228	166399	CHIL3846 Abbott Sensor Based Glucose Monitoring System Paediatric Study (BEAGLE)	Number Agreed	13	13	Date Agreed	31/05/2015	10	29/05/2015	Withdrawn By Sponsor
13/SC/0268	124775	CCRN2100 (Cystic fibrosis)	Number Agreed	3	3	Date Agreed	31/07/2015	1	06/08/2015	Recruitment Finished
14/YH/1124	160884	EXTEND (2819MA1002)	Number Agreed	3	3	Date Agreed	28/02/2016	0	04/02/2016	Recruitment Finished
13/WM/0143	116688	Study of Moxetumomab Pasudotox in pALL or LL of B-Cell	Number Agreed	1	1	Date Agreed	31/01/2016	2	01/09/2015	Recruitment Finished
14/NI/1075	161871	CHIL3670 (ALX0171-C104)	Number Agreed	1	1	Date Agreed	31/03/2016	0	10/09/2015	Withdrawn By Host
14/NE/1099	144103	GA29103: PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFlixIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAIVE TO TNF INHIBITORS	Number Agreed	1	1	Date Agreed	31/12/2017	0	08/09/2015	Withdrawn By Sponsor
14/SC/0181	148882	Elagolix in Endometriosis Associated Pain - Extension	Number Agreed	1	1	Date Agreed	31/12/2015	1	31/12/2015	Recruitment Finished
15/SC/0054	171682	CheckMate 238 (Nivolumab vs Ipilimumab in Melanoma)	Number Agreed	6	6	Date Agreed	30/06/2016	4	07/09/2015	Withdrawn By Sponsor
14/LO/1490	158617	CANC-3574 - Nivolumab (BMS-936558) in Stage III (unresectable) or stage IV Melanoma (CA209-172)	Number Agreed	3	3	Date Agreed	30/10/2015	3	18/01/2016	Recruitment Finished
14/YH/1090	158372	QUIET-1	Number Agreed	4	4	Date Agreed	31/12/2015	0	08/10/2015	Withdrawn By Sponsor
15/LO/0920	181642	SMTC11004: Paediatric Subjects with Duchenne Muscular Dystrophy (DMD)	Number Agreed	1	1	Date Agreed	19/02/2016	1	18/02/2016	Recruitment Finished